Categories | p | HR | 95% CI | |
---|---|---|---|---|
Disease-free interval | ||||
FOXA1 positivity | FOXA1 ≥ 1% versus < 1% | 0.009 | 0.58 | 0.39–0.87 |
Pathologic tumor size | pT ≥ 20 mm versus < 20 mm | 0.047 | 1.46 | 1.01–2.12 |
Distant metastasis | M1 versus M0–MX | < 0.0001 | 5.05 | 2.41–10.56 |
Overall survival | ||||
FOXA1 positivity | FOXA1 ≥ 1% versus < 1% | 0.030 | 0.70 | 0.50–0.96 |
Pathologic tumor size | pT ≥ 20 mm versus < 20 mm | 0.001 | 1.69 | 1.24–2.30 |
Distant metastasis | M1 versus M0–MX | 0.005 | 2.82 | 1.36–5.82 |
Cancer-specific survival | ||||
FOXA1 positivity | FOXA1 ≥ 1% versus < 1% | 0.032 | 0.65 | 0.44–0.96 |
Pathologic tumor size | pT ≥ 20 mm versus < 20 mm | 0.004 | 1.69 | 1.18–2.42 |
Pathologic nodal stage | pN+ versus pN0–pNX | 0.002 | 1.83 | 1.26–2.66 |
Distant metastasis | M1 versus M0–MX | 0.001 | 3.47 | 1.66–7.23 |